Health Officials Push Back on HPV Vaccine Rumors as School Campaign Rolls Out
As Chinese schools roll out notices for HPV vaccination, parents' group chats are circulating claims that the shots disrupt development and periods. Disease-control officials are pushing back with blunt, line-by-line myth-busting — and a crash course on why age 13 matters.
The notices have gone out through Chinese schools this autumn: girls in their first year of junior high are being offered HPV vaccination, in some places free of charge. And right on schedule, the parent group chats are churning with worry. "Will it affect her development?" "Will it mess up her periods?" This week the question formally reached the trending list, framed as the rumour it is: HPV vaccines do not disrupt development or menstruation — that claim is typical misinformation.
The rumour and the reply
The debunking came from Henan's provincial disease-control centre, whose immunisation specialists sat for a public Q&A aimed squarely at the parents' most-cited anxieties. Their reply was unusually direct. The HPV vaccines used in China are made with recombinant technology and contain neither viral genetic material nor hormones, they explained — nothing in the shot touches the endocrine system, so it cannot cause early puberty, stunt growth or throw off a cycle. Common side effects are the mundane ones: a sore arm, mild redness at the injection site.
The specialists also walked parents through the choice many are agonising over: whether to take the free bivalent vaccine offered through the school programme, or to wait and pay for the nine-valent shot marketed against more strains. Their framing — the best vaccine is the one taken before any exposure, and at 13 the immune response is strongest — pushed back against the idea that waiting is the careful option.
Why the state is hurrying
Cervical cancer is the target the programme is aimed at: national figures put it among the top five cancers in Chinese women, with more than 150,000 new cases and around 56,000 deaths in 2022 — and the incidence curve has been rising and getting younger for two decades. School-based vaccination, which targets girls at 13 before exposure risk begins, is how countries that have bent that curve did it, and China's provinces have been phasing into the model with free bivalent doses.
That is the context the parents' chat rumours are operating against, and why the rebuttal this week was not left to comment sections: a school-notice season meets a rumour season, and uptake is the whole game. Health communicators have learned that silence lets "it affects development" travel from one class group to the next in an afternoon.
The race now is between rollout and rumour: whether the school programmes hold their uptake rates as they expand to more provinces is what to watch.